GENE THERAPY FOR LYSOSOMAL DISORDERS

EA054658B1Active Publication Date: 2026-09-23PREVAIL THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
EA202490491
Authority / Receiving Office
EA · EA
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-03-12
Filing Date
2020-04-10
Publication Date
2026-09-23
Estimated Expiration
2040-04-10

Smart Images

  • Figure 00000071_0000
    Figure 00000071_0000
  • Figure 00000071_0001
    Figure 00000071_0001
  • Figure 00000072_0000
    Figure 00000072_0000
Patent Text Reader

Abstract

The invention relates to compositions and methods for treating diseases associated with aberrant lysosomal function, such as frontotemporal dementia (FTD). The invention also provides expression constructs comprising a transgene encoding progranulin, or a portion thereof. The invention provides methods for treating FTD by administering such expression constructs to a subject in need thereof.
Need to check novelty before this filing date? Find Prior Art

Claims

1. A method for the quantitative assessment of progranulin protein (PGRN) in a cerebrospinal fluid (CSF) sample from a subject known to have or suspected of having frontotemporal dementia (FTD), comprising: (a) dilution of the CSF sample in a master mix containing dithiothreitol (DTT) and sample buffer; (b) loading the diluted CSF sample, anti-PGRN antibody, a secondary antibody that detects anti-PGRN antibody, luminol, and peroxide into the wells of a capillary cartridge; (c) loading the capillary cartridge into an automated Western blot immunoassay instrument; (d) using an automated Western blot immunoassay instrument to calculate signal intensity, peak area, and signal-to-noise ratio; and (e) quantification of the PGRN protein level in the CSF sample as the peak area of ​​immunoreactivity to the anti-PGRN antibody, where the CSF sample was taken from a subject who had previously been administered a recombinant adeno-associated virus (rAAV) containing: (i) an rAAV vector containing a nucleic acid comprising, in order from 5' to 3': (a) ITR of adeno-associated virus 2 (AAV2); (b) cytomegalovirus (CMV) enhancer; (c) chicken beta-actin promoter (CBA); (d) a transgene insert encoding a PGRN protein, wherein the transgene insert comprises the nucleotide sequence of SEQ ID NO: 68; (e) woodchuck hepatitis virus post-transcriptional regulatory element (WPRE); (f) the polyA signal tail of bovine growth hormone; and (g) AAV2 ITR; and (ii) capsid protein of adeno-associated virus (AAV).

2. The method according to claim 1, wherein the CSF sample is taken from a human.

3. The method of claim 1, wherein the FTD is FTD with a GRN mutation.

4. The method of claim 1, wherein the CSF sample is taken from a non-human primate.

5. The method according to claim 1, wherein the AAV capsid protein is an AAV9 capsid protein.

6. The method according to any one of claims 1 to 5, wherein the dilution step is a 4-fold dilution.